2014年9月20日土曜日
エボラ熱定義(EU)
Ebola virus disease case definition for reporting in EU
http://www.ecdc.europa.eu/en/healthtopics/ebola_marburg_fevers/EVDcasedefinition/Pages/default.aspx
AND any of the following:
OR a person who died suddenly and inexplicably
OR
http://www.ecdc.europa.eu/en/healthtopics/ebola_marburg_fevers/EVDcasedefinition/Pages/default.aspx
Clinical criteria
Any person currently presenting or having presented before death:- Fever ≥38.6°C
- Severe headache
- Vomiting, diarrhoea, abdominal pain
- Unexplained haemorrhagic manifestations in various forms
- Multi-organ failure
Laboratory criteria
Any of the following:- Detection of Ebola virus nucleic acid in a clinical specimen and confirmation by sequencing or a second assay on different genomic targets.
- Isolation of Ebola virus from a clinical specimen.
Epidemiological criteria
In the 21 days before the onset of symptoms:- having been in an affected area;
- having had contact with a probable or confirmed EVD case.
High-risk exposure criteria
Any of the following:- close face-to-face contact (e.g. within one metre) without appropriate personal protective equipment (including eye protection) with a probable or confirmed case who was coughing, vomiting, bleeding, or who had diarrhoea; or had unprotected sexual contact with a case up to three months after recovery;
- direct contact with any material soiled by bodily fluids from a probable or confirmed case;
- percutaneous injury (e.g. with needle) or mucosal exposure to bodily fluids, tissues or laboratory specimens of a probable or confirmed case;
- participation in funeral rites with direct exposure to human remains in or from an affected area without appropriate personal protective equipment;
- direct contact with bats, rodents, primates, living or dead, in or from affected areas, or bushmeat.
登録:
投稿 (Atom)
noteへ実験的移行
禁煙はお早めに! 米国における人種・民族・性別による喫煙・禁煙での死亡率相違|Makisey|note 日常生活内の小さな身体活動の積み重ねが健康ベネフィットをもたらす:VILPA|Makisey|note
-
禁煙はお早めに! 米国における人種・民族・性別による喫煙・禁煙での死亡率相違|Makisey|note 日常生活内の小さな身体活動の積み重ねが健康ベネフィットをもたらす:VILPA|Makisey|note
-
米国では、Potiga (ezogabine):ポティガ(エゾガビン)、国際的には、レチガビン [RTG ]で、従来の抗てんかん薬剤と異なるメカニズムで、KCNQ2-5 (K(v) 7.2-7.5) ion channelのpositive allosteric modulato...
-
Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes Joel G. Ray, et. al. JAMA. 2016;316(9):952-961. doi:...